ReviewHematology. American Society of Hematology. Education Program2017
Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis.
Review in Hematology. American Society of Hematology. Education Program, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06965998 (A Pilot Randomized Double-Blinded Comparison of Full Treatment Dose Rivaroxaban for 90 Days to Prophylactic Dose Rivaroxaban for 45 Days in Patients With Lower Extremity Superficial Vein Thrombosis), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Randomized Double-Blinded Comparison of Full Treatment Dose Rivaroxaban for 90 Days to Prophylactic Dose Rivaroxaban for 45 Days in Patients With Lower Extremity Superficial Vein Thrombosis
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2024Pooled it
- Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial.Circulation. Cardiovascular quality and outcomes · 2021Trial
- Age and waist circumference as key determinants of postoperative thrombosis and squatting recovery after unicompartmental knee arthroplasty.Aging clinical and experimental research · 2025Article
- Current Diagnostic and Therapeutic Challenges in Superficial Venous Thrombosis.Medicina (Kaunas, Lithuania) · 2024Review
- Superficial Venous Thrombosis: A Comprehensive Review.Healthcare (Basel, Switzerland) · 2024Review
- Prediction of Venous Thromboembolism in Diverse Populations Using Machine Learning and Structured Electronic Health Records.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV).Medicina (Kaunas, Lithuania) · 2023Article
- Medicine and Phlebolymphology: Time to Change?Journal of clinical medicine · 2020Review
- Superficial venous thrombosis: is it as benign as we think?Journal of thrombosis and thrombolysis · 2020Article
- [The conspicuous leg].Der Internist · 2018Review
- Incidence of deep vein thrombosis and pulmonary embolism in Asian patients after direct anterior total hip arthroplasty.Journal of orthopaedicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of superficial vein thrombosis (SVT) is poorly defined and remains controversial overall. SVT has long been considered a benign, self-limited disease, but recent studies show that SVT carries a nonnegligible risk for recurrence, deep vein thrombosis, or pulmonary embolism. Current guidelines recommend the use of low-molecular-weight heparin or fondaparinux, but results of several surveys indicate that the majority of patients with SVT receive nonanticoagulant therapy only, which includes compression stockings or bandages, nonsteroidal anti-inflammatory drugs, topical application of heparin gel, or surgical interventions. However, several recent observational and interventional studies provide better insight into the optimal treatment of patients with SVT who are at different risks for thromboembolic complications. This educational review summarizes the available evidence and aims to provide practical guidance based on a clinical decision pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.